Artificial Intelligence

A new vectorized antibody therapy for ALS, VTx-002, has been granted FDA Fast Track status, accelerating its path to patients battling the disease.

The medtech firm's preliminary results show a Q4 revenue uptick but miss yearly estimates, signaling a stabilizing but cautious path forward for 2026.

With an expanded Boehringer Ingelheim deal and a new CMO, Enara Bio is set to take its novel 'Dark Antigen' therapy into human trials in 2026.

A looming 10-million-ton copper deficit threatens to derail the AI revolution and the green energy transition, sparking a new era of geopolitical competition.

Replicate Bioscience secures major funding to develop next-gen self-replicating RNA vaccines, aiming for more durable and accessible global health solutions.

Cybersecurity firm Corero appoints an award-winning leader to supercharge its partner program, signaling a major push in the competitive DDoS defense market.

AI data platform Protege raises its Series A to $65M, tackling the critical data bottleneck with an ethical, licensing-first model for real-world data.

With major backing from Goldman Sachs, a biotech firm is advancing a potentially life-changing gene therapy for a rare, progressive form of blindness.

Everest Group recognizes CGI's role in India's booming GCC market, where hubs for digital transformation and AI now balance innovation with efficiency.

CN Energy's robotics arm, Pathenbot, just won a key "Investment-Ready" award at CES 2026. What does this reveal about its disruptive tech and global plans?

The software giant is launching AI-powered AP automation, mobile payments, and integrated financing to tackle contractor cash flow and operational headaches.

How a blend of private capital and pragmatic regulation is turning Singapore into a global hub for longevity research, pushing scientific and ethical boundaries.

As the eVTOL race intensifies, Vertical Aerospace appoints key execs from Lotus, Nike, and AB InBev to spearhead its push for certification and scale.

China approves Aizhida, a novel once-daily ADHD medication. Its unique dual-action formula provides rapid and sustained symptom control, aiming to transform treatment.

A $10 billion fund. Two competing visions. Wingspan Advisors' unique 'Alpha Summit' will decide the future of its ambitious new investment vehicle.

A landmark deal brings a leading U.S. venue management platform to Japan, South Korea, and Taiwan, aiming to transform fan safety and operations.

CEO Werner Lanthaler will present FairJourney Bio's data-driven antibody discovery platform at the elite J.P. Morgan conference, signaling major growth.

Oculis is advancing a neuroprotective drug for optic neuropathies and a first-of-its-kind eye drop for diabetic macular edema, aiming at $10B+ markets.

Pharma giant Bayer partners with biotech innovator Soufflé to develop a groundbreaking siRNA therapy, aiming to deliver genetic medicine directly to the heart.

The UK retail giant is ditching manual spreadsheets for an AI-driven platform to standardize labor and enhance customer experience across 240+ stores.